[Skip to content]

EPDA - European Parkinsons Disease Association EPDA - European Parkinsons Disease Association EPDA - Awareness EPDA - Coping Strategies EPDA - Medical Information EPDA - Patient Guide EPDA - Site Map EPDA - Rewrite Tomorrow
EUROPEAN PARKINSON'S DISEASE ASSOCIATION
.

Research papers

As a voice for Parkinson’s in Europe, the EPDA actively works to raise awareness on all issues relating to Parkinson’s.  One of the ways in which we are working to achieve this, is by maintaining a directory of research activities from around the world in relation to the disease symptoms, mechanisms and treatment that can improve the lives of people with Parkinson’s, their families and carers.  

This resource is aimed at healthcare professionals, people with Parkinson’s and their families, researchers and our member organisations. Our aim is to provide evidence based information to support the introduction and use of medications, best practices and treatments that will improve quality of life.

Research papers have been grouped for ease of searching.  You can also find research papers listed by specific symptomatology and treatment areas on the Rewrite Tomorrow website.

Search

Links to research papers relating to Parkinson's disease symptoms are provided below.

(Links go to the Rewrite Tomorrow website.)

Motor symptoms

Non-motor symptoms



Research news RSS feed

Latest research papers

  • Neuron Modeling Parkinson's Disease Using Induced Pluripotent Stem CellsTo more effectively model PD, researchersgenerated two patient-derived iPSC lines: a line carrying a homozygous p.G2019S mutation in the leucine-rich repeat kinase 2 (LRRK2) gene and another carrying a full gene triplication of the α-synuclein encoding gene, SNCA. 01 June 2012
  • World people Low serum uric acid concentration in Parkinson's disease in southern SpainThis study produced consistent findings that UA might have a protective effect against Parkinson's disease and could influence its clinical progression. 12 May 2012
  • Neuron Sustained translational repression by eIF2α-P mediates prion neurodegenerationGiven the prevalence of protein misfolding and activation of the unfolded protein response in several neurodegenerative diseases, these results suggest that manipulation of common pathways such as translational control, rather than disease-specific approaches, may lead to new therapies preventing synaptic failure and neuronal loss across the spectrum of these disorders. 06 May 2012
  • Brain scan How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorderPatients with idiopathic REM sleep behaviour disorder in an ongoing cohort study were evaluated annually with several quantitative motor measures, including the Unified Parkinson's Disease Rating Scale, Purdue Pegboard, alternate-tap test and timed up-and-go. Patients who developed parkinsonism were identified from this cohort and matched according to age to normal controls. 04 May 2012
  • Chemical structure Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's diseaseNo significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects. 03 May 2012
  • DNA Role for α6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian miceTo conclude, the similar declines in L-dopa-induced AIMs in nicotine-treated wildtype mice and in α6(-/-) mice treated with and without nicotine indicate an essential role for α6β2* nAChRs in the maintenance of L-dopa-induced AIMs. These findings suggest that α6β2* nAChR drugs have potential for reducing L-dopa-induced dyskinesias in Parkinson's disease. 03 May 2012
  • Quality of Life Friends Couple walking in woods Physiological Phenotype and Vulnerability in Parkinson's DiseaseBecause much of the mitochondrial burden created by this at-risk phenotype is created by Ca2+ entry through L-type voltage-dependent channels for which there are antagonists approved for human use, a neuroprotective strategy to reduce this burden is feasible. 02 May 2012
  • Man with stick Short and valid assessment of apraxia in Parkinson's diseaseNo association was found between the AST and MDS-UPDRS part III, indicating that AST discriminates well (discriminative validity) between apraxia and parkinsonism. Furthermore, AST was associated with ADL and Hoehn & Yahr stage (convergent validity). 01 May 2012
  • Neuron Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical reviewOn the other hand it has been observed that certain aspects of cognitive performance may decline after DBS, namely when the therapeutic target is the widely used subthalamic nucleus. These are important pieces of information for patients, their families, and health care professionals. This manuscript reviews these aspects and their clinical implications. 26 April 2012
  • Neuron Piecing together the puzzle of progression and mortality in Parkinson's diseaseVu et al. have undertaken a complex modeling analysis of a clinical trial dataset to investigate predictors and associations of progression of multiple features Parkinson's disease. Their multifaceted approach is a valuable addition to the literature. In agreement with prior studies, they find that age and UPDRS scores are predictive of future progression. 12 April 2012
Page: [1] [2] [3]
[ Next » ]


RSS
RSS feed - Subscribe to this page